TW200716632A - Integrase inhibitor compounds - Google Patents

Integrase inhibitor compounds

Info

Publication number
TW200716632A
TW200716632A TW095117351A TW95117351A TW200716632A TW 200716632 A TW200716632 A TW 200716632A TW 095117351 A TW095117351 A TW 095117351A TW 95117351 A TW95117351 A TW 95117351A TW 200716632 A TW200716632 A TW 200716632A
Authority
TW
Taiwan
Prior art keywords
inhibitor compounds
integrase inhibitor
integrase
compounds
hiv
Prior art date
Application number
TW095117351A
Other languages
English (en)
Inventor
Zhenhong R Cai
Rachael A Lansdown
Salman Y Jabri
Samuel E Metobo
Hao-Lun Jin
Michael R Mish
Choung U Kim
Richard M Pastor
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of TW200716632A publication Critical patent/TW200716632A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW095117351A 2005-05-16 2006-05-16 Integrase inhibitor compounds TW200716632A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68169005P 2005-05-16 2005-05-16

Publications (1)

Publication Number Publication Date
TW200716632A true TW200716632A (en) 2007-05-01

Family

ID=37432118

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095117351A TW200716632A (en) 2005-05-16 2006-05-16 Integrase inhibitor compounds

Country Status (5)

Country Link
US (1) US20070072831A1 (zh)
EP (1) EP1888581A2 (zh)
AR (1) AR057023A1 (zh)
TW (1) TW200716632A (zh)
WO (1) WO2006125048A2 (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
EP1973908A2 (en) * 2005-12-21 2008-10-01 Gilead Sciences, Inc. Processes and intermediates useful for preparing integrase inhibitor compounds
WO2007136714A2 (en) * 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
CA2665698A1 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
CL2007002953A1 (es) * 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
US20090291921A1 (en) * 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
EP3085377A1 (en) 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
KR101700267B1 (ko) * 2008-07-25 2017-01-26 비이브 헬쓰케어 컴퍼니 화합물
EP2350091B1 (en) * 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
SG10201703086VA (en) 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
CN102245182B (zh) 2008-12-11 2014-07-23 盐野义制药株式会社 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
CN107011260A (zh) 2008-12-11 2017-08-04 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010279678B2 (en) 2009-08-03 2015-09-10 Emergent Biodefense Operations Lansing Llc Composition and methods of treating viral infections and viral induced tumors
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
JP5752136B2 (ja) 2009-10-14 2015-07-22 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スピロ−オキシインドール化合物のための合成方法
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
EP4556010A3 (en) 2011-11-30 2025-07-23 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013102936A1 (en) * 2012-01-03 2013-07-11 Council Of Scientific & Industrial Research N-(3-((diethylamino) methyl)-4-hydroxyphenyl)-n-(quinolin-4-yl) sulfonamides for the treatment of tuberculosis and process of preparation thereof
KR20150014506A (ko) 2012-05-23 2015-02-06 사피라 파르마슈티칼즈 게엠베하 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체
US9434745B2 (en) 2012-05-23 2016-09-06 Savira Pharmaceuticals Gmbh 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2015524457A (ja) 2012-08-06 2015-08-24 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ジヒドロキシピリミジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防における使用
NZ709260A (en) 2012-12-21 2016-07-29 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP2016508145A (ja) 2013-01-08 2016-03-17 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用
AR094378A1 (es) 2013-01-08 2015-07-29 Savira Pharmaceuticals Gmbh Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral
CN104903319B (zh) 2013-01-08 2017-05-31 萨维拉制药有限公司 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (zh) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (zh) 2014-06-20 2018-06-23
CA2953862A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
SI3466490T1 (sl) 2015-04-02 2020-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US11180758B2 (en) 2016-02-24 2021-11-23 The Johns Hopkins University Antiviral proteins and their uses in therapeutic methods
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
EP3494998A1 (en) 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
IL319022A (en) 2017-12-11 2025-04-01 Univ Muenchen Tech PSMA imaging and endoradiotherapy ligands
EP3494999A1 (en) 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
CN113677375B (zh) 2019-01-30 2024-07-23 慕尼黑工业大学 氟化硅受体取代的放射性药物及其前体
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2118069T3 (es) * 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO2000036132A1 (en) * 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
WO2001027309A1 (en) * 1999-10-13 2001-04-19 Merck & Co., Inc. Hiv integrase inhibitors
AU1152702A (en) * 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2456155A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
BRPI0409873A (pt) * 2003-04-28 2006-05-16 Tibotec Pharm Ltd inibidores da integrase do hiv
EP1678322A2 (en) * 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005117904A2 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
JP5289046B2 (ja) * 2005-05-19 2013-09-11 メルク カナダ インコーポレイテッド Ｅｐ４アンタゴニストとしてのキノリン誘導体

Also Published As

Publication number Publication date
WO2006125048A3 (en) 2007-08-09
WO2006125048A2 (en) 2006-11-23
US20070072831A1 (en) 2007-03-29
EP1888581A2 (en) 2008-02-20
AR057023A1 (es) 2007-11-14

Similar Documents

Publication Publication Date Title
TW200716632A (en) Integrase inhibitor compounds
WO2007136714A3 (en) Integrase inhibitors
WO2009067541A3 (en) Integrase inhibitors
PL1742642T3 (pl) Analogi fosfonianowe związków inhibitorów integrazy HIV
TW200640924A (en) VEGF-R2 inhibitors and methods
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
TW200734315A (en) Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
NO20071050L (no) Rapamycin-polymorf II og anvendelser derav
NO20052378D0 (no) Pre-organiserte trisykliske integraseinhibitorforbindelser
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
PL1761520T3 (pl) Inhibitory kinazy
WO2012002741A3 (en) Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
TNSN08191A1 (en) Kinase inhibitors
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
TW200624426A (en) BACE inhibitors
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
MY142105A (en) Leukotriene biosynthesis inhibitors
UA85505C2 (en) Kinase inhibitors
TW200732281A (en) Heterocyclic CETP inhibitors
TWI374886B (en) Processes for preparing intermediates of pemetrexed
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives